Ascendis Pharma A/S (ASND)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | -- | -- | 1960 |
Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | -- | -- | 1974 |
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | -- | -- | 1961 |
Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | -- | -- | 1971 |
Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer | -- | -- | 1969 |
Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | -- | -- | 1961 |
Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | -- | -- | 1979 |
Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology | -- | -- | 1974 |
Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | -- | -- | 1969 |
Ms. Sherrie Glass | Chief Business Officer | -- | -- | -- |
Ascendis Pharma A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,017
Description
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Corporate Governance
Upcoming Events
September 1, 2025 at 10:59 AM UTC - September 5, 2025 at 12:00 PM UTC
Ascendis Pharma A/S Earnings Date